Skip to content
AnalystLens
Back to VRTXIncome Statement

VERTEX PHARMACEUTICALS INC / MA Revenue 2008-2026 | VRTX

Annual FY2008–FY2025 · quarterly through Q1 FY2026

Latest annual · FY2025

$12.00B

+8.9%YoY vs FY2024Source: 10-KFY2025

From $175.5M in FY2008 to $12.00B in FY2025: 68.4× in 17 years.

By quarter▲▼ vs a year before
Fiscal yearQ1Q2Q3Q4
FY26$3.0B+7.8%Not reportedNot reportedNot reported
FY25$2.8B+3.0%$3.0B+12.1%$3.1B+11.0%$3.2B+9.5%
FY24$2.7B+13.3%$2.6B+6.1%$2.8B+11.6%$2.9B+15.7%
FY23$2.4B+13.2%$2.5B+13.5%$2.5B+6.4%$2.5B+9.3%
FY22$2.1B+21.6%$2.2B+22.5%$2.3B+17.7%$2.3B+11.1%
Share23%24%25%27%

Shaded by size: darkest is the largest quarter shown; ringed is the latest reported; a dash marks a quarter with no separate figure. Each quarter sits by its period-end date. Share: its typical part of the fiscal year.

Key Statistics

Trend DirectionGrowing
CAGR

+14.1%

FY2020
$6.21B
FY2025
$12.00B

5 years selected · on the chart

01—History

Revenue History

Year-over-year comparison from 10-K annual reports

  18. $12.00B
YoY changeLargest recent move+64.9%in FY16Latest +8.9%

1 older move runs past ±100% (largest +883.9%); point at, tap or drag across the bars to read one.

02—Ledger

Revenue, period by period

PeriodValueChangeSource
FY2025$12.00B+8.9%10-K
FY2024$11.02B+11.7%10-K
FY2023$9.87B+10.5%10-K
FY2022$8.93B+17.9%10-K
FY2021$7.57B+22.1%10-K
FY2020$6.21B+49.1%10-K
FY2019$4.16B+36.6%10-K
FY2018$3.05B+22.5%10-K
FY2017$2.49B+46.2%10-K
FY2016$1.70B+64.9%10-K
FY2015$1.03B+77.9%10-K
FY2014$580.4M−52.1%10-K
FY2013$1.21B−20.6%10-K
FY2012$1.53B+8.3%10-K
FY2011$1.41B+883.9%10-K
FY2010$143.4M+40.7%10-K
FY2009$101.9M−41.9%10-K
FY2008$175.5M—10-K

03—Questions

What is revenue?

Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.

What is VERTEX PHARMACEUTICALS INC / MA's current revenue?

VERTEX PHARMACEUTICALS INC / MA (VRTX) annual revenue for 2025 was $12.00B, a 8.90% increase from 2024. VERTEX PHARMACEUTICALS INC / MA revenue for the quarter ending March 31, 2026 was $2.99B.

What was VERTEX PHARMACEUTICALS INC / MA's revenue in 2024?

VERTEX PHARMACEUTICALS INC / MA annual revenue for 2024 was $11.02B, a 11.66% increase from 2023.

What was VERTEX PHARMACEUTICALS INC / MA's revenue in 2023?

VERTEX PHARMACEUTICALS INC / MA annual revenue for 2023 was $9.87B, a 10.51% increase from 2022.

What is VERTEX PHARMACEUTICALS INC / MA's 5-year revenue CAGR?

VERTEX PHARMACEUTICALS INC / MA revenue grew at a compound annual growth rate (CAGR) of 14.10% from FY2020 to FY2025, going from $6.21B to $12.00B over 5 years.

Company
VERTEX PHARMACEUTICALS INC / MA
Ticker
VRTX
Sector
Healthcare
Industry
Pharmaceutical Preparations
View company profile →